Author: Angeline Leishman|| Date Published: December 30, 2021
Merck’s life science business has been awarded a three-year, $136.7 million contract to stand up a factory for a critical material needed to manufacture rapid COVID-19 point-of-care tests.
MilliporeSigma said Thursday it will use the funds to establish a lateral flow membrane production facility in Sheboygan, Wisconsin, to support domestic production and supply efforts for the government’s pandemic preparedness initiative.
The business supplies its Hi-Flow Plus nitrocellulose membrane to manufacturers of medical test kits intended to diagnose infectious diseases such as COVID-19, malaria and HIV.
NexTech Solutions, a mission-driven provider of edge-focused software and services, has acquired Vidterra, a developer of edge-deployed video distribution software, to…
Sally Wallace has been promoted to executive vice president and chief operating officer at Leonardo DRS. The Arlington, Virginia-based company said Tuesday…